Source: Annual Congress 2006 - Difficult tuberculosis cases
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Z. I. Kryvasheyeva (Minsk, Belarus). Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources. Eur Respir J 2006; 28: Suppl. 50, 280

Member's Comments

No comment yet.

Related content which might interest you: Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Choice and adherence in preventive treatment for tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017 Using results of drug sensitivity of infection source in initial chemotherapy choice in TB children and teenagers Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017 Year: 2017 Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 The influence of modern microbiological methods on the antibiotic treatment of pneumonia in children Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes Year: 2018